Lv2
160 积分 2024-02-06 加入
Macrophages: versatile players in renal inflammation and fibrosis
5天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
1个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
1个月前
已完结
Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry
1个月前
已完结
Pembrolizumab plus enfortumab vedotin in urothelial cancer
2个月前
已完结
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy
2个月前
已完结
Overcoming tumour resistance in cancer immunotherapy through predictive and pharmacodynamic biomarkers
2个月前
已完结
Exploring the next generation of antibody–drug conjugates
3个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
3个月前
已完结
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
4个月前
已完结
皖公网安备34019202002308
